01—Abstract
Summary
Summary of the 10-K filed February 27, 2017. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. ("Exelixis") reported total revenues of $191.5 milliona for 2016, up from $37.2 million in 2015, driven by the April 2016 U.S. launch of CABOMETYX for previously treated advanced renal cell carcinoma (RCC) and by collaboration revenue from its Ipsen agreement.
Net product revenues were $135.4 millionb, including $93.5 million from CABOMETYX and $41.9 million from COMETRIQ. Net loss narrowed to $70.2 million from $161.7 million in 2015, and the company reported a $2.0 billion accumulated deficit. Cash and investments rose to $479.6 million at December 31, 2016, from $253.3 million a year earlier, after the Ipsen upfront and milestone payments and the retirement of the 4.25% 2019 Notes through exchanges and redemption.
The company's near-term value depends on expanding cabozantinib. Management plans to submit a supplemental NDA in 2017 for first-line advanced RCC based on the CABOSUN phase 2 trial, and top-line results from the phase 3 CELESTIAL trial in hepatocellular carcinoma are anticipated in 2017. In January 2017 Exelixis signed a Takeda collaboration for Japan, with a $50.0 millionc upfront payment received in February 2017, and in February 2017 it entered into clinical collaborations with Bristol-Myers Squibb and Roche.
Cotellic, marketed by Genentech, is a second potential revenue source, but Exelixis is in arbitration with Genentech over cost and revenue allocations. The balance sheet carries $189.1 milliond of debt at year-end, including the Deerfield Notes, which management intends to repay on or about July 1, 2017, and an $80.0 million Silicon Valley Bank term loan due May 31, 2017. Deferred revenue of $256.8 million from the Ipsen agreement is a significant liability that will be recognized over the life of the collaboration.
02—Key points
Key Highlights
- Total revenues of $191.5 million in 2016, up from $37.2 million in 2015, with net product revenues of $135.4 million led by CABOMETYX ($93.5 million) following its April 2016 FDA approval
- Net loss narrowed to $70.2 million in 2016 from $161.7 million in 2015; accumulated deficit of $2.0 billion
- Cash and investments of $479.6 million at December 31, 2016, versus $253.3 million a year earlier
- Ipsen collaboration: $200.0 million upfront in March 2016, a $60.0 million milestone in November 2016, and up to $254.0 million in additional development and regulatory milestones; deferred revenue totaled $256.8 million at year-end
- Retired all $287.5 million of the 4.25% 2019 Notes through exchanges and redemption in 2016, issuing 54,009,279 common shares
- Planned 2017 catalysts include the first-line advanced RCC sNDA based on CABOSUN and top-line results from the CELESTIAL phase 3 trial in advanced HCC
- Debt maturities: $80.0 million term loan due May 31, 2017, and Deerfield Notes ($125.0 million principal at maturity July 1, 2018) that the company intends to prepay on or about July 1, 2017 at 105% of principal
03—Questions
Frequently Asked Questions
What drove the increase in Exelixis's 2016 revenue?
Total revenues rose to $191.5 million from $37.2 million. Net product revenues increased by $101.2 million, primarily from the commercial launch of CABOMETYX in late April 2016, and collaboration revenues increased by $53.1 million, mainly from upfront payments and milestones under the Ipsen agreement.
What is the status of cabozantinib's development beyond approved indications?
CABOMETYX is approved for previously treated advanced RCC in the U.S. and EU. The company is working toward a 2017 sNDA for first-line advanced RCC based on the CABOSUN trial, which met its primary PFS endpoint. The phase 3 CELESTIAL trial in second-line HCC has top-line results expected in 2017, and a phase 3 trial with nivolumab in first-line RCC is expected to begin in 2017.
What is the dispute with Genentech over Cotellic?
Exelixis filed a demand for arbitration on June 3, 2016, asserting claims related to Genentech's clinical development, pricing and commercialization of Cotellic and cost and revenue allocations. Genentech withdrew its counterclaim on December 29, 2016 and changed its promotional expense allocation approach, but other significant issues remain in dispute, and the company states the ultimate outcome is difficult to predict.
How is Exelixis financing its debt obligations?
Cash and short-term investments held at December 31, 2016 are expected to be used to repay debt. The company must pay the $80.0 million Silicon Valley Bank term loan on May 31, 2017, and it intends to repay the Deerfield Notes on or about July 1, 2017 at a prepayment price equal to 105% of outstanding principal plus accrued interest.
Is Exelixis expected to be profitable soon?
The filing states the company has incurred net losses since inception, except in fiscal 2011, and expects to continue incurring substantial operating expenses. It states that the company will need to generate substantial revenues to achieve and maintain profitability, and it does not provide a profitability timeline.
04—Continue